Here using patient-derived xenograft models of SCLC, we present a highly sensitive and accurate technology for quantifying PARP inhibitors and target engagement in vivo in support of the clinical relevance of [18F]PARPi for treatment monitoring and prediction. This evidence concerns the gene PARP1 and small cell lung carcinoma.